ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SANA vs DNA // 10Y YIELD & FRED MACRO BETA

Sana Biotechnology Inc. (NASDAQ) VS. Ginkgo Bioworks Holdings Inc. (Class A) (NYSE) • 15-METRIC TALLY: SANA 2 — DNA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SANA VS. DNA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SANA DNA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -17.78% -21.80% +4.02 SANA /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -0.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — -25.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 SANA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.1 52.0 -5.82 DNA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $814.3M $819.7M -$5.4M DNA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SANA REV DNA REV SANA GROSS % DNA GROSS % SANA FCF DNA FCF
FY 2025 $0 $170.2M — — -$144.8M -$178.7M
FY 2024 $0 $227.0M — — -$256.6M -$382.1M
FY 2023 $0 $251.5M — — -$253.6M -$295.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SANA // BETA —
DNA // BETA —